Financial PerformanceBiotricity reported a doubling of free cash flow compared to FY2Q25 on an 11% increase in sales to $3.6M.
Market ExpansionBiotricity's partnerships with top group purchasing organizations and specialist organizations in neurology and pulmonology are gaining traction.
Product InnovationProduct innovation remains a catalyst as the next-generation, cellular-enabled Biocore Pro gains traction, and strategic partnerships extend Biotricity’s remote monitoring algorithms into new markets.